RBC Comments on Gilead Sciences (GILD) Harvoni Week 1 NRx
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 16 Hold, 2 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 43
Join SI Premium – FREE
RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $115. Comments follow week 1 IMS scripts for Harvoni, which totaled 444 vs 151 for week1 Sovaldi. Wolters Kluwer data showed 501 new Harvoni scripts, the report noted.
Analyst Michael J. Yee said, "Initial data looks positive vs our calculations for both WK and IMS."
"Approx 30% of Sovaldi is used in GT2/3 and not applicable to Harvoni which is G1-only so apples-to-apples each week should back out ~30% of Sovaldi scripts. The "total franchise" combining Harvoni + Sovaldi NRx is 444 + 1683 = 2127, which is +16% over last week's Sovaldi NRx," he added.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $107.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Upgrades Airbus SE (AIR:FP) (EADSY) to Outperform, 'positive shift in sentiment has room to run'
- RBC Capital Upgrades Vistry Group PLC (VTY:LN) to Sector Perform, 'Veni Vidi Vistry'
- HSBC Downgrades DFI Retail Group Holdings (DFI:SP) (DFILF) to Hold, 'expect H&B to progress more slowly'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!